UNSPSC 51432809: Lisinopril anhydrous

This classification denotes an ace inhibitor with the molecular formula C21H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q3P4BS2FD, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, but more generally known as lisinopril anhydrous, which bears US NIH Compound Identifier 5362119. European Medicines Agency schedules lisinopril anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG.

Most nations, for tariff purposes, schedule lisinopril anhydrous under HS 29339990. Lisinopril anhydrous bears US NLM identifiers UMLS ID C2827257 and NCI Concept Code C83924. SMILES: C1CCC(CC1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)O.

UNSPSC 51432809 Lisinopril anhydrous, a Commodity code, represents specific pharmaceutical active ingredients and finished-dose medications that state and local governments procure for emergency medical services, healthcare facilities, and pharmacy benefit programs. Recent state and local opportunities show that purchasing under this code spans emergency life-support medications supplied to fire rescue operations, wholesale generic pharmaceuticals distributed through multistate cooperative purchasing networks, and direct-to-manufacturer prescription programs operated by state health agencies. Issuing bodies include municipal fire departments (via city purchasing offices), state health and human services commissions, and multistate cooperative purchasing alliances serving both state agencies and local government facilities. The scope of work involves supplying FDA-compliant medications with firm expiration-date minimums, often through authorized wholesaler networks, with vendors responsible for regulatory compliance (cGMP, DSCSA, OSHA HCS), comprehensive insurance coverage, and performance guarantees against product defects.

Activity under the code concentrates in Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, a $40,000 award with a Small Local Business Enterprise set-aside and five-percent bid discount capped at $10,000, due April 8, 2026. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP in January 2026 for Generic Multi-Source Pharmaceuticals and OTC Products with responses due March 26, 2026, serving state and local facilities across Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission issued a Request for Information in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing early-stage procurement planning for direct state contracting with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.